KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 77 filers reported holding KALA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,570,000 | +1063.0% | 189,845 | +586.5% | 0.00% | – |
| Q4 2018 | $135,000 | -75.3% | 27,655 | -50.0% | 0.00% | – |
| Q3 2018 | $546,000 | +42.2% | 55,310 | +97.5% | 0.00% | – |
| Q2 2018 | $384,000 | -13.3% | 28,003 | 0.0% | 0.00% | -100.0% |
| Q1 2018 | $443,000 | +14.2% | 28,003 | +33.3% | 0.00% | – |
| Q4 2017 | $388,000 | +16.9% | 21,006 | +44.6% | 0.00% | – |
| Q3 2017 | $332,000 | – | 14,528 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |